SENS study to assess feasibility, effectiveness and family experience of introducing SMA screening into the NHS newborn screening programme
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Biogen paid Ionis a US $ 60 million one-time upfront payment
Subscribe To Our Newsletter & Stay Updated
